Buscar
01/01/2023
Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen
Trifunov S., Natera-De Benito D., Carrera-García L., Codina A., Expósito-Escudero J., Ortez C., Medina J., Alcala, ST, Bernal S., Alias L., Badosa C., Balsells S., Alcolea D., Nascimento A., Jimenez-Mallebrera C.. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen. Journal Of Neuromuscular Diseases. 2023; 10(4)DOI:10.3233/JND-230012. PMID:37038823. IF:3.200(Q2/3D).
01/01/2023
Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society
Hamlett E.D., Flores-Aguilar L., Handen B., Potier M.-C., Granholm A.-C., Sherman S., Puig V., Santoro J.D., Carmona-Iragui M., Rebillat A.-S., Head E., Strydom A., Busciglio J.. Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society. Molecular Syndromology. 2023; 14(2)DOI:10.1159/000526021. PMID:37064334. IF:0.900(Q4/10D).
01/01/2023
Multifocal Transcranial Direct Current Stimulation in Primary Progressive Aphasia Does Not Provide a Clinical Benefit Over Speech Therapy
Borrego-Écija S., Montagut N., Martín-Trias P., Vaqué-Alcázar L., Illán-Gala I., Balasa M., Lladó A., Casanova-Mollà J., Bargalló N., Valls-Solé J., Lleó A., Bartrés-Faz D., Sánchez-Valle R.. Multifocal Transcranial Direct Current Stimulation in Primary Progressive Aphasia Does Not Provide a Clinical Benefit Over Speech Therapy. JOURNAL OF ALZHEIMERS DISEASE. 2023; 93(3)DOI:10.3233/JAD-230069. PMID:37182884. IF:3.400(Q2/4D).
01/01/2023
Compounded inequality: racial disparity and Down syndrome
McGlinchey E., Iulita M.F., Fortea J.. Compounded inequality: racial disparity and Down syndrome. Lancet Public Health. 2023; 8(11)DOI:10.1016/S2468-2667(23)00213-X. PMID:. IF:(Q/D).